The combination of gamma secretase inhibitor (GSI) showed increased BCMA surface density on tumor cells and decreased soluble BCMA levels in the peripheral blood in an immunodeficient mouse model, therefore enhancing the efficacy of BCMA CAR-T cells (Fig. 1B). Here, TNFRSF17 is linked to neoplasm.